Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Supprelin LA Prior Auth Coverage | Ope…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0118

    Supprelin LA (histrelin) (Subcutaneous Implant)

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0118 alerts

    Get alerted when Policy IC-0118 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy IC-0118 defines prior authorization, dosing limits, indications, renewal criteria, and billing/coding for Supprelin LA (histrelin) implants for members of Viva Health.

    Policy Summary
    PayerViva Health
    PolicySupprelin LA (histrelin) (Subcutaneous Implant)
    Policy CodePolicy IC-0118
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for the implant; initial PA is valid for 12 months and may be renewed every 12 months.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsinitial prior authorization duration
    1 unit / 12 monthsmaximum billable units
    ages 2 to <13CPP age range
    J9226HCPCS code
    NDC 67979-0002-xx

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    NDC
    7covered ICD-10 codes (Appendix 1)

    Coverage Criteria

    Initial Therapy - Central Precocious Puberty

    Covered when ALL of the following are met

    CPP initial criteria: Member is between the ages of 2 and less than 13 years; AND will not be used in combination with growth hormone; AND onset of secondary sexual characteristics earlier than age 8 for females and 9 for males associated with pubertal pituitary gonadotropin activation; AND diagnosis is confirmed by pubertal gonadal sex steroid levels and a pubertal luteinizing hormone (LH) response to stimulation by native GnRH; AND bone age advanced greater than 2 standard deviations beyond chronological age; AND tumor has been ruled out by laboratory tests and appropriate diagnostic imaging (e.g., brain imaging to rule out intracranial tumor, pelvic/testicular/adrenal ultrasound to rule out steroid‑secreting tumors) and hCG levels to rule out chorionic gonadotropin‑secreting tumor.all

    Initial Therapy - Gender Dysphoria

    Covered when ALL of the following are met

    Gender Dysphoria initial criteria: Member has experienced pubertal development to at least Tanner stage 2 (applies to members <18 years); AND member has a diagnosis of gender dysphoria confirmed by a qualified mental health professional (MHP) or by DSM‑5‑TR criteria; AND a qualified MHP has confirmed persistent/intense gender dysphoria, worsening with onset of puberty, addressed coexisting psychological/medical/social problems that could interfere with treatment, and assessed capacity to give informed consent; AND member has been informed of effects and side effects of treatment including potential loss of fertility and options to preserve fertility; AND informed consent obtained and parents/guardians are involved when the adolescent lacks legal medical consent capacity; AND for adolescents, a pediatric endocrinologist or clinician experienced in pubertal assessment has confirmed agreement with the indication for treatment and that there are no medical contraindications to treatment.all

    Continuation / Renewal Criteria

    Renewal provided when ALL of the following are met

    Universal renewal criteria: Member continues to meet the universal criteria and other indication‑specific relevant criteria identified in section III; AND absence of unacceptable toxicity from the drug (examples include severe implant site reactions, convulsions/seizures, psychiatric events such as emotional lability, severe cutaneous adverse reactions including SJS/TEN, DRESS, AGEP, and signs/symptoms of pseudotumor cerebri/idiopathic intracranial hypertension).all
    CPP renewal response: Member is less than 13 years of age; AND disease response demonstrated by lack of progression or stabilization of secondary sexual characteristics, decrease in height velocity, decrease in the ratio of bone age to chronological age (BA:CA), and improvement in final height prediction.all
    Gender Dysphoria renewal response: Member has shown a beneficial response to treatment as evidenced by routine monitoring of clinical pubertal development (if applicable) and applicable laboratory parameters.

    For the Central Precocious Puberty (CPP) initial approval pathway, the policy explicitly excludes concurrent administration with growth hormone. The coverage criteria state that the implant will not be used in combination with growth hormone, and all other CPP initial criteria (age, biochemical confirmation, advanced bone age, and tumor exclusion) must be met for coverage to be considered.

    In the list of covered ICD-10 diagnosis codes, F64.9 (Gender identity disorder, unspecified) is noted as discontinued effective 10/1/26. The appendix replaces or updates related gender identity disorder codes effective on that date, including the introduction of F64.A (Gender identity disorder, in remission).

    Initial Therapy and Dosing

    Initial Therapy / Dosing

    Initial dosing and indication rules

    Dose and frequency: For both Central Precocious Puberty and Gender Dysphoria indications: 1 implant (50 mg) inserted subcutaneously every 12 months.all

    Continuation and Renewal

    Continuation Therapy

    Renewal/continuation requirements

    Continuation nodes: Member continues to meet initial criteria; AND there is absence of unacceptable toxicity from the drug (examples listed in renewal criteria); AND evidence of clinical response per indication‑specific measures (CPP: stabilization or decreased progression of secondary sexual characteristics, decreased height velocity, decreased BA:CA ratio, and improved final height prediction; Gender Dysphoria: beneficial response on routine monitoring of pubertal development and applicable laboratory parameters).all

    Billing & Coding

    Covered HCPCS CodesHCPCSCovered
    J9226Histrelin implant (Supprelin LA), 50 mg; 1 billable unit = 50 mg
    NDCNDC
    67979-0002-xxSupprelin LA 50 mg implant NDC
    Covered ICD-10 Diagnosis CodesICD-10Covered
    E30.1Precocious puberty
    E30.8Other disorders of puberty
    F64.0Transsexualism
    F64.1Dual role transvestism
    F64.2Gender identity disorder of childhood
    F64.8Other gender identity disorders
    F64.9Gender identity disorder, unspecified (Discontinued effective 10/1/26)
    F64.AGender identity disorder, in remission (Effective 10/1/26)
    Medicare Part B Jurisdiction notesmixed
    No codes listed
    Max units per time
    Maximum billable units1 billable unit (50 mg) per 12 months
    HCPCS unit definition1 billable unit = 50 mg
    Time windowPer 12-month period
    Supprelin LA (histrelin) — quantity limit summary
    ProductSupprelin LA (histrelin) 50 mg implant
    HCPCS codeJ9226 - Histrelin implant (Supprelin LA), 50 mg

    Provider Actions & Requirements

    Prior Authorization

    Prior authorization validity

    Prior authorization is required for Supprelin LA. Initial prior authorization validity will be provided for 12 months (365 days) and may be renewed every 12 months (365 days) thereafter.

    Prior Authorization

    PA applies for covered diagnoses (see Appendix 1)

    Prior authorization is applied to Supprelin LA with covered diagnoses listed in Appendix 1; the NQTL checklist indicates PA was considered for the indication and for drug cost.

    • Covered diagnoses are those listed in Appendix 1 (e.g., E30.1, E30.8, F64.0, F64.1, F64.2, F64.8, F64.9, F64.A).
    Step Therapy

    No step therapy requirement documented

    Step Therapy

    StepRequirement
    1No step therapy or prerequisite medication failures specified in this portion of the policy.
    StepPolicy note
    1No specific step therapy algorithm provided; prior authorization consideration is driven by indication and drug cost per the NQTL checklist.

    Definitions

    Qualified mental health professional (MHP)
    Minimum qualificationsLicensed by statutory body and hold at minimum a master's degree or equivalent in a relevant clinical field
    Diagnostic competenceCompetent using ICD (latest edition) for diagnosis; other taxonomies allowed where ICD not implemented
    Clinical skillsAble to identify coexisting mental health or psychosocial concerns and distinguish from gender dysphoria
    Consent assessmentAble to assess capacity to consent for treatment
    Experience and educationExperience or qualification to assess clinical aspects of gender dysphoria and participation in continuing education
    Precocious puberty

    Background

    Supprelin LA is a subcutaneous histrelin implant used for indications that include suppression of puberty. For Central Precocious Puberty (CPP), the policy requires age and biochemical confirmation, advanced bone age, and exclusion of tumors prior to coverage. The policy’s Appendix 1 lists covered diagnosis codes for CPP and related puberty and gender identity disorders to guide billing and authorization.

    Quantity Limits

    Supprelin LA (histrelin) — 1
    Product identifierSupprelin LA (histrelin) — 50 mg implant
    Billing codeJ9226 (Histrelin implant, 50 mg) — 1 billable unit = 50 mg
    Quantity restrictionLimited to 1 implant (50 mg) per 12 months

    Site of Care

    Note

    Office insertion every 12 months (site-of-care)

    The histrelin implant (Supprelin LA) is administered as 1 implant (50 mg) inserted subcutaneously every 12 months; the policy specifies the office as the site of care for insertion.

    • Dose/frequency: 1 implant (50 mg) every 12 months
    • Site-of-care: office (implant inserted subcutaneously)

    Revision History

    2026-07-01policy_last_reviewLatest

    Policy IC-0118 (Supprelin LA) last reviewed and NQTL checklist updated to note that indication and cost were considered 'Consider for PA' for prior authorization design; utilization management methods may include prior authorization.

    Policy Summary
    PayerViva Health
    PolicySupprelin LA (histrelin) (Subcutaneous Implant)
    Policy CodePolicy IC-0118
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization for the implant; initial PA is valid for 12 months and may be renewed every 12 months.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy and DosingContinuation and RenewalBilling & CodingProvider Actions & RequirementsStep TherapyDefinitionsBackgroundQuantity LimitsSite of CareRevision History
    all
    Quantity limit
    1 implant (50 mg) per year (1 billable unit / 12 months)

    No step therapy or prerequisite medication failures are specified in this policy for Supprelin LA.

    Step Therapy

    Step therapy not specified — PA considered by NQTL

    The policy does not provide a specific step therapy algorithm; the NQTL review notes that prior authorization may be considered based on indication and cost.

    Documentation Required

    Required documentation for Gender Dysphoria

    For the Gender Dysphoria indication, documentation must include a diagnosis confirmed by a qualified mental health professional (or DSM-5-TR criteria), confirmation of persistent/intense gender dysphoria and worsening with puberty, assessment of capacity to consent, informed consent including discussion of potential loss of fertility and options to preserve fertility, parental/guardian involvement when applicable, and for adolescents agreement from a pediatric endocrinologist or clinician experienced in pubertal assessment.

    • Diagnosis confirmed by a qualified MHP or DSM-5-TR criteria
    • MHP confirmation of persistent/intense dysphoria and that puberty worsened dysphoria
    • Documentation of informed consent and fertility counseling
    • Pediatric endocrinologist or experienced clinician confirmation for adolescents
    Documentation Required

    Required documentation for Central Precocious Puberty (CPP)

    For Central Precocious Puberty (CPP), documentation must confirm pubertal gonadal sex steroid levels and a pubertal luteinizing hormone (LH) response to native GnRH stimulation, bone age advanced >2 standard deviations beyond chronological age, and diagnostic imaging/laboratory testing ruling out intracranial or steroid/chorionic gonadotropin–secreting tumors.

    • Pubertal gonadal sex steroid levels and pubertal LH response to GnRH stimulation
    • Bone age >2 SD advanced beyond chronological age
    • Imaging and labs to rule out tumors (brain imaging, pelvic/testicular/adrenal ultrasound, hCG levels)
    Documentation Required

    Medicare coverage determinations must be followed

    Medicare members are subject to applicable Medicare coverage determinations (NCD/LCD/LCA) and must follow those policies where relevant; additional indications may be applied at the discretion of the health plan.

    • Medicare Part B covered diagnosis codes: N/A (per Appendix 2)
    • Search NCD/LCD/LCA via CMS Medicare Coverage Database when applicable
    Denial Risk

    Renewal may be denied for unacceptable toxicity

    Renewal may be denied if there is unacceptable toxicity from the drug; examples include severe implant site reactions, convulsions/seizures, severe psychiatric events, severe cutaneous adverse reactions (e.g., SJS/TEN, DRESS, AGEP), and signs/symptoms of pseudotumor cerebri/idiopathic intracranial hypertension.

    • Severe implant site reactions
    • Convulsions/seizures
    • Psychiatric events (emotional lability, aggression, etc.)
    • Severe cutaneous adverse reactions (SJS/TEN, DRESS, AGEP)
    • Signs/symptoms of pseudotumor cerebri/idiopathic intracranial hypertension (headache, papilledema, visual changes)
    Denial Risk

    PA may be applied based on NQTL findings (indication & cost)

    The NQTL checklist indicates prior authorization may be used based on the indication and the cost of the drug; utilization management methods like PA were considered in the NQTL assessment.

    • NQTL conclusions: Indication — Consider for PA; Cost of drug — Consider for PA
    Note

    Office insertion every 12 months (site-of-care)

    The histrelin implant (Supprelin LA) is administered as 1 implant (50 mg) inserted subcutaneously every 12 months; the policy specifies the office as the site of care for insertion.

    • Dose/frequency: 1 implant (50 mg) every 12 months
    • Site-of-care: office (implant inserted subcutaneously)
    ICD-10 codeE30.1
    DescriptionPrecocious puberty
    LocationListed in Appendix 1 as a covered diagnosis code